Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $22.3600 (0.36%) ($22.3600 - $22.3600) on Wed. Aug. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.94% (three month average) | RSI | 8 | Latest Price | $22.3600(0.36%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TGTX declines -12.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) ARKK(60%) IBB(60%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -1.97% in a week (0% probabilities). VIXM(-46%) VXX(-40%) UUP(-20%) IGOV(-8%) UNG(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.97% (StdDev 3.94%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-16.75(-174.91%) | Resistance Level | $27.52 | 5 Day Moving Average | $22.44(-0.36%) | 10 Day Moving Average | $22.79(-1.89%) | 20 Day Moving Average | $27.52(-18.75%) | To recent high | -44.7% | To recent low | 0.9% | Market Cap | $2.832b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |